Jeffrey Norton
Investigate Role of Metabolic Imaging in Predicting Tumor Response/Outcome After Pancreatic CA Tx
Contact Information
Stanford University School of Medicine 300 Pasteur Drive Stanford, CA 94305Brief
To test the ability of new imaging techniques to monitor and predict response of pancreatic cancer to radiation and/or chemotherapy.
Recruiting Status:
CompletedStanford Recruiting Status:
CompletedCondition(s):
Intervention(s):
- Procedure: PET Scan
- Drug: FLT
- Drug: FDG
Phase:
N/AEligibility
Ages Eligible for Study:
18 years to Any AgeGenders Eligible for Study:
Male and FemaleHealth of Volunteers:
People with the conditions listed in this trial can participate as controls.Key Inclusion Criteria:
- Adult patients (>18) with histologically confirmed adenocarcinomas of the pancreas with a - treatment plan consisting of definitive or palliative radiation therapy and/or chemotherapy with or without surgery.
- Negative urine pregnancy test if a woman of child-bearing potential (WOCBP).
- WOCBP must be using an adequate method of contraception to avoid pregnancy throughout the study period.
- All patients will be evaluated in a uniform manner at the Stanford GI Combined Modality Tumor Board to determine eligibility.
Key Exclusion Criteria:
1. Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.
2. Any concurrent malignancy other than non-melanomaskin cancer, or carcinomainsitu of the cervix. Patients with a previous malignancy without evidence of disease for >5 years will be allowed to enter the trial.
3. WOCBP who is pregnant or breastfeeding.
4. Inability to sign written consent.
Additional Study Details
Official Title:
Pilot Study to Investigate the Role of Metabolic Imaging in Predicting Tumor Response and Outcome After Therapy for Pancreatic CancerAnticipated start date:
10/1/2006Lead Sponsor:
Stanford UniversityInvestigator(s):
Study Type:
InterventionalPurpose:
DiagnosticAllocation:
Non-randomizedMasking:
OpenControl:
noneAssignment:
Single GroupEndpoints:
Safety/EfficacyPrimary Outcomes:
- Evaluate the performance of the novel imaging methods described above.
Secondary Outcomes:
- Correlate FLT activity with clinical outcomes
Total Number to be Enrolled:
30Total Number to be Enrolled at Stanford:
5More Information
Secondary ID(s):
- 95733
- PANC0004
Locations & Contacts
Stanford Locations & Contacts:
Stanford University School of Medicine 300 Pasteur Drive Stanford, CA 94305Non-Stanford Locations:
The Stanford website does not have any locations outside of Stanford listed for this trial. You may want to check clinicaltrials.gov for posible additional locations.
This listing was last updated:
4/17/2009PLEASE NOTE:
Study Coordinators and Research Nurses cannot give medical advice over the phone. Telephone numbers are provided for obtaining additional information on specific clinical research trials only. If you have specific questions which require clinical expertise, please call your primary care physician. If you do not have a primary care physician please feel free to call the SHC Physician Referral Service at (800) 756-9000 or send an email.
Help
Trial Administration